Summary of news (with links)

• FDA approves Gilead’s Trodelvy® (sacituzumab govitecan) for metastatic triple-negative breast cancer. - https://www.gilead.com/news-and-press/press-room/press-releases/2021/4/fda-approves-trodelvy-the-first-treatment-for-metastatic-triplenegative-breast-cancer-shown-to-improve-progressionfree-survival-and-overall-surviv
• NICE 'no' for Opdivo/Yervoy lung cancer combo. - http://www.pharmatimes.com/news/nice_no_for_opdivoyervoy_lung_cancer_combo_1366600
• FDA grants accelerated approval to Trodelvy® for the treatment of metastatic urothelial cancer. - https://www.gilead.com/news-and-press/press-room/press-releases/2021/4/us-fda-grants-accelerated-approval-to-trodelvy-for-the-treatment-of-metastatic-urothelial-cancer
• Astrazeneca's Tagrisso approved in China for adjuvant treatment of EGFR-mutated NSCLC. - https://www.precisiononcologynews.com/regulatory-news-fda-approvals/astrazenecas-tagrisso-approved-china-adjuvant-treatment-egfr-mutated#.YHm_oBP7S_t
• Bristol Myers Squibb receives European Commission approval for Opdivo® (nivolumab) in combination with Cabometyx® (cabozantinib) as first-line treatment for patients with advanced renal cell carcinoma. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-in-Combination-with-Cabometyx-cabozantinib-as-First-Line-Treatment-for-Patients-with-Advanced-Renal-Cell-Carcinoma/default.aspx
• FDA approves Opdivo® (nivolumab) in combination with chemotherapy for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of PD-L1 expression status. - https://news.bms.com/news/corporate-financial/2021/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-in-Combination-with-Chemotherapy-for-Patients-with-Advanced-or-Metastatic-Gastric-Cancer-Gastroesophageal-Junction-Cancer-and-Esophageal-Adenocarcinoma/default.aspx
• Amgen's investigational targeted treatment bemarituzumab granted breakthrough therapy designation. - https://www.amgen.com/newsroom/press-releases/2021/04/amgens-investigational-targeted-treatment-bemarituzumab-granted-breakthrough-therapy-designation
• Seagen and Astellas announce FDA acceptance of two supplemental biologics license applications for Padcev® (enfortumab vedotin-ejfv) in locally advanced or metastatic urothelial cancer. - https://investor.seagen.com/press-releases/news-details/2021/Seagen-and-Astellas-Announce-U.S.-FDA-Acceptance-of-Two-Supplemental-Biologics-License-Applications-for-PADCEV-enfortumab-vedotin-ejfv-in-Locally-Advanced-or-Metastatic-Urothelial-Cancer/default.aspx
• European Commission approves GSK’s Jemperli (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. - https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-gsk-s-jemperli-dostarlimab-the-first-anti-pd-1-therapy-approved-for-recurrent-or-advanced-endometrial-cancer/
• ADC Therapeutics announces FDA approval of Zynlonta™ (loncastuximab tesirine-lpyl) in relapsed or refractory diffuse large B-cell lymphoma. - https://ir.adctherapeutics.com/press-releases/press-release-details/2021/ADC-Therapeutics-Announces-FDA-Approval-of-ZYNLONTA-loncastuximab-tesirine-lpyl-in-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma/default.aspx
• Bristol Myers Squibb receives positive CHMP opinion for Onureg® (azacitidine tablets; CC-486) as frontline oral maintenance therapy for adults with acute myeloid leukemia in first remission. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Onureg-azacitidine-tablets-CC-486-as-Frontline-Oral-Maintenance-Therapy-for-Adults-with-Acute-Myeloid-Leukemia-in-First-Remission/default.aspx
• Bristol Myers Squibb receives positive CHMP opinion recommending approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) as first-line treatment for unresectable malignant pleural mesothelioma. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Unresectable-Malignant-Pleural-Mesothelioma/default.aspx
• Tagrisso recommended for approval in the EU by CHMP for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. - https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/tagrisso-adjuvant-receives-positive-chmp-opinion.html
• FDA grants priority review for new drug application for Takeda's mobocertinib (TAK-788) as a treatment for EGFR exon20 insertion+ metastatic NSCLC. - com/newsroom/newsreleases/2021/takeda-announces-u.s.-fda-grants-priority-review-for-new-drug-application-for-mobocertinib-tak-788-as-a-treatment-for-egfr-exon20-insertion-metastatic-non-small-cell-lung-cancer/
• FDA advisory committee votes in favor of maintaining accelerated approval of Genentech's Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer. - https://www.gene.com/media/press-releases/14907/2021-04-27/fda-advisory-committee-votes-in-favor-of
• FDA advisory committee votes in favor of maintaining accelerated approval of Genentech’s Tecentriq for previously untreated metastatic bladder cancer. - https://www.gene.com/media/press-releases/14908/2021-04-28/fda-advisory-committee-votes-in-favor-of
• Seagen and Genmab announce FDA filing acceptance for priority review of tisotumab vedotin biologics license application for patients with recurrent or metastatic cervical cancer. - https://investor.seagen.com/press-releases/news-details/2021/Seagen-and-Genmab-Announce-U.S.-FDA-Filing-Acceptance-for-Priority-Review-of-Tisotumab-Vedotin-Biologics-License-Application-for-Patients-with-Recurrent-or-Metastatic-Cervical-Cancer/default.aspx
• Enhertu® (trastuzumab deruxtecan) now available via the cancer drugs fund for the treatment of HER2 positive metastatic breast cancer. - https://www.businesswire.com/news/home/20210420005171/en

• Guardant Health receives New York State CLEP approval for Guardant Reveal blood test to detect and monitor residual disease in patients with early-stage cancer. - https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Receives-New-York-State-CLEP-Approval-for-Guardant-Reveal-Blood-Test-to-Detect-and-Monitor-Residual-Disease-in-Patients-with-Early-Stage-Cancer/default.aspx
• Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy. - https://www.roche.com/media/releases/med-cor-2021-04-23.htm
• French Ministry of Health decision to modify the national price list for Healthcare Services. - https://www.eurofins-biomnis.com/wp-content/uploads/2021/04/JO078_010421.pdf

• City of Hope scientists develop a novel, non invasive liquid biopsy test for identification of lymph node metastasis in early-stage T1 colorectal cancer. - https://www.businesswire.com/news/home/20210421005225/en/City-of-Hope-Scientists-Develop-a-Novel-Noninvasive-Liquid-Biopsy-Test-for-Identification-of-Lymph-Node-Metastasis-in-Early-Stage-T1-Colorectal-Cancer
• Dermtech introduces PLAplus with improved sensitivity for early detection of melanoma. - https://www.businesswire.com/news/home/20210422005262/en
• Castle Biosciences presents data demonstrating DecisionDx-Melanoma as significant, independent predictor of recurrence in stage I cutaneous melanoma population. - https://ir.castlebiosciences.com/news-releases/news-release-details/castle-biosciences-presents-data-demonstrating-decisiondx-0
• Biodesix announces intent to launch liquid biopsy NGS test. - https://www.biodesix.com/newsroom/press-releases/biodesix-announces-intent-to-launch-liquid-biopsy-next-generation-sequencing-test-with-unprecedented-turnaround-time
• Genome Medical expands technology infrastructure to accelerate delivery of virtual genomic medicine. - https://resources.genomemedical.com/genome-medical-expands-technology-infrastructure-to-accelerate-delivery-of-virtual-genomic-medicine
• Armed with $55m in new funding, Nucleix to further invest in early-stage lung cancer Dx. - https://www.genomeweb.com/molecular-diagnostics/armed-55m-new-funding-nucleix-further-invest-early-stage-lung-cancer-dx#.YHaYhRP7S_s
• Volastra Therapeutics extends seed financing to $44 million to advance drug discovery programs to prevent cancer metastasis. - https://www.volastratx.com/volastra-therapeutics-extends-seed-financing-to-44-million-to-advance-drug-discovery-programs-to-prevent-cancer-metastasis/
• Veristat announces WindRose Health Investors as new investment partner. - https://www.veristat.com/news/veristat-announces-new-investment-partner-windrose-health-investors
• Nucleix secures $55 million funding led by RA Capital Management and additional prominent life science investors to advance Lung Epicheck® for early detection of lung cancer. - https://www.businesswire.com/news/home/20210407005322/en/
• Immunoscape raises $14m to advance deep immunomics platform for high-dimensional immune profiling and drug discovery. - https://immunoscape.com/immunoscape-raises-14m-to-advance-deep-immunomics-platform-for-high-dimensional-immune-profiling-and-drug-discovery/
• Deciphex led consortium secure €3m to develop novel prognostic tests to avoid overtreatment of cancer patients. - https://www.deciphex.com/deciphex-led-consortium-secure-3m-to-develop-novel-prognostic-tests-to-avoid-overtreatment-of-cancer.html
• KScan® Bioinformatics process receiving Japanese Patent No 6832294 for a method of assessing protein modification status and identifying biomarkers linked to cell signalling pathways.- https://www.linkedin.com/posts/kinomica_pharma-bioinformatics-proteomics-activity-6785522792042397696-LbI5; https://www.kinomica.com/

• FDA accepts Investigational New Drug Application for Exelixis' XB002 in patients with advanced solid tumors. - https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-accepts-investigational-new-drug
• Novocure announces FDA IDE approval and steering committee for KEYNOTE-B36 trial evaluating tumor treating fields together with pembrolizumab in non-small cell lung cancer. - https://www.novocure.com/novocure-announces-fda-ide-approval-and-steering-committee-for-keynote-b36-trial-evaluating-tumor-treating-fields-together-with-pembrolizumab-in-non-small-cell-lung-cancer/
• Bristol Myers Squibb announces Opdivo (nivolumab) plus chemotherapy and Opdivo plus Yervoy (ipilimumab) demonstrate superior survival benefit compared to chemotherapy in unresectable advanced or metastatic esophageal squamous cell carcinoma. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Announces-Opdivo-nivolumab-plus-Chemotherapy-and-Opdivo-plus-Yervoy-ipilimumab-Demonstrate-Superior-Survival-Benefit-Compared-to-Chemotherapy-in-Unresectable-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspx
• DESTINY-CRC02 Phase 2 Trial of ENHERTU® initiated in patients with HER2-overexpressing advanced colorectal cancer. - https://www.daiichisankyo.com/files/news/pressrelease/pdf/202104/20210407_E.pdf
• LintonPharm announces authorization from China health authority (NMPA) to proceed with a Phase 1/2 trial evaluating catumaxomab for the treatment of non-muscle invasive bladder cancer. - http://www.lintonpharm.com/LINTONPHARM-ANNOUNCES-AUTHORIZATION-FROM?_l=en&article_id=14
• Mirati Therapeutics reports investigational adagrasib (MRTX849) preliminary data as well as initial MRTX1133 preclinical data. - https://www.biospace.com/article/releases/mirati-therapeutics-reports-investigational-adagrasib-mrtx849-preliminary-data-demonstrating-tolerability-and-durable-anti-tumor-activity-as-well-as-initial-mrtx1133-preclinical-data/
• Merck’s Keytruda® (pembrolizumab) demonstrated superior disease-free survival (DFS) compared with placebo as adjuvant therapy in patients with renal cell carcinoma (RCC) following surgery. - https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-superior-disease-free-survival-dfs-compared-with-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-rcc-following-surgery/
• Bristol Myers Squibb announces Opdivo (nivolumab) plus chemotherapy and Opdivo plus Yervoy (ipilimumab) demonstrate superior survival benefit compared to chemotherapy in unresectable advanced or metastatic esophageal squamous cell carcinoma. - https://news.bms.com/news/corporate-financial/2021/Bristol-Myers-Squibb-Announces-Opdivo-nivolumab-plus-Chemotherapy-and-Opdivo-plus-Yervoy-ipilimumab-Demonstrate-Superior-Survival-Benefit-Compared-to-Chemotherapy-in-Unresectable-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma/default.aspx
• SLFN11 expansion demonstrates potential as a predictive biomarker in SCLC. - https://www.targetedonc.com/view/slfn11-expansion-demonstrates-potential-as-a-predictive-biomarker-in-sclc
• Neoadjuvant Opdivo (nivolumab) plus chemotherapy significantly improves pathologic complete response in patients with resectable non-small cell lung cancer in phase 3 CheckMate -816 trial. - https://news.bms.com/news/corporate-financial/2021/Neoadjuvant-Opdivo-nivolumab-Plus-Chemotherapy-Significantly-Improves-Pathologic-Complete-Response-in-Patients-with-Resectable-Non-Small-Cell-Lung-Cancer-in-Phase-3-CheckMate--816-Trial/default.aspx
• Merck advances ATR inhibitor berzosertib in small cell lung cancer with new published data and initiation of Phase II trial with registrational intent. - https://www.merckgroup.com/en/news/berzosertib-cancer-cell.html
• Novocure announces update on Phase 3 pivotal LUNAR trial of tumor treating fields in non-small cell lung cancer. - https://www.novocure.com/novocure-announces-update-on-phase-3-pivotal-lunar-trial-of-tumor-treating-fields-in-non-small-cell-lung-cancer/
• Veracyte announces key milestone in companion diagnostics program with Acerta Pharma using LymphMark lymphoma subtyping test. - https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-key-milestone-companion-diagnostics-program
• Istari Oncology announces FDA clearance of IND to initiate LUMINOS-103: a basket trial evaluating the safety and efficacy for PVSRIPO in patients with advanced solid tumors. - https://istarioncology.com/istari-oncology-announces-fda-clearance-of-ind-to-initiate-luminos-103/
• Istari Oncology announces publication of Phase 1 data showing PVSRIPO immunotherapy leads to objective responses in patients with treatment-refractory melanoma. - https://istarioncology.com/istari-oncology-announces-publication-of-phase-1-data/
• Candel Therapeutics completes enrollment in Phase 1 clinical trial of CAN-2409 in combination with Opdivo® (nivolumab) for the treatment of high-grade gliomas. - https://www.candeltx.com/press-release/candel-therapeutics-completes-enrollment-in-phase-1-clinical-trial-of-can-2409/

• Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. - https://www.cell.com/cell/fulltext/S0092-8674(21)00294-4
• InterVenn’s glycoproteomic-based biomarker signature successfully predicts favorable outcomes in metastatic malignant melanoma patients treated with checkpoint inhibitors. - https://www.businesswire.com/news/home/20210412005237/en/InterVenn%E2%80%99s-Glycoproteomic-based-Biomarker-Signature-Successfully-Predicts-Favorable-Outcomes-in-Metastatic-Malignant-Melanoma-Patients-Treated-with-Checkpoint-Inhibitors
• Castle Biosciences announces prospective, multi-center publication demonstrating DecisionDx®-Melanoma as significant, independent predictor of patient outcomes in cutaneous melanoma. - https://ir.castlebiosciences.com/news-releases/news-release-details/castle-biosciences-announces-prospective-multi-center
• Castle Biosciences' i31-GEP artificial intelligence algorithm improves precision of sentinel lymph node positivity prediction in cutaneous melanoma. - https://ir.castlebiosciences.com/news-releases/news-release-details/late-breaking-new-independent-validation-study-1674-patients
• Sagasafe® technology utilized in new study of ESR1 mutations in breast cancer. - https://sagadiagnostics.com/sagasafe-technology-utilized-in-new-study-of-esr1-mutations-in-breast-cancer/
• Veracyte announces publication of study showing robust performance of Percepta GSC in improving lung cancer diagnosis. - https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-publication-study-showing-robust-performance
• Study shows Guardant Reveal™ Blood-Only liquid biopsy test predicts risk for colorectal cancer recurrence. - https://investors.guardanthealth.com/press-releases/press-releases/2021/Study-Shows-Guardant-Reveal-Blood-Only-Liquid-Biopsy-Test-Predicts-Risk-for-Colorectal-Cancer-Recurrence-with-Industry-Leading-Sensitivity/default.aspx

• Merck completes acquisition of Pandion Therapeutics. - https://www.merck.com/news/merck-completes-acquisition-of-pandion-therapeutics/
• Euformatics eyes global expansion in NGS Informatics. - https://www.genomeweb.com/informatics/euformatics-eyes-global-expansion-ngs-informatics#.YG1VwBP7S_s
• Acornmed selects Twist Bioscience technology to power next generation precision medicine tests. - https://www.biospace.com/article/releases/acornmed-selects-twist-bioscience-technology-to-power-next-generation-precision-medicine-tests/
• DiaSorin to acquire Luminex corporation for USD 37.00 per share or approximately USD 1.8 billion. - https://diasoringroup.com/sites/diasorincorp/files/allegati_pressrel/diasorin_to_acquire_luminex_corporation.pdf
• Tango Therapeutics and BCTG Acquisition Corp. announce merger agreement to create publicly listed precision medicine company focused on the next generation of targeted cancer therapies. - https://www.tangotx.com/press_releases/tango-therapeutics-and-bctg-acquisition-corp-announce-merger-agreement-to-create-publicly-listed-precision-medicine-company-focused-on-the-next-generation-of-targeted-cancer-therapies/
• Agilent completes acquisition of Resolution Bioscience, expands role in fast-growing NGS market for precision oncology. - https://www.agilent.com/about/newsroom/presrel/2021/15apr-gp21013.html
• Thermo Fisher Scientific to acquire PPD. - https://thermofisher.mediaroom.com/2021-04-15-Thermo-Fisher-Scientific-to-Acquire-PPD-Inc-a-Leading-Clinical-Research-Organization
• European Commission to assess proposed acquisition of Grail by Illumina. - https://ec.europa.eu/commission/presscorner/detail/en/mex_21_1846
• Amgen successfully completes acquisition of Five Prime Therapeutics. - https://www.amgen.com/newsroom/press-releases/2021/04/amgen-successfully-completes-acquisition-of-five-prime-therapeutics

• Volastra Therapeutics partners with Microsoft to advance metastatic cancer research. - https://www.volastratx.com/volastra-therapeutics-partners-with-microsoft-to-advance-metastatic-cancer-research/
• OncoDNA and myNEO join forces to unlock the power of mRNA therapeutics. - https://www.oncodna.com/en/company/activity/news-list/personalized-mRNA-vaccines-cancer-patients-myNEO/
• PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration. - https://psioxus.com/psioxus-therapeutics-updates-agreement-with-bristol-myers-squibb-to-advance-their-clinical-stage-immuno-oncology-collaboration/
• TriSalus Life Sciences and MD Anderson announce strategic research collaboration to evaluate treatment of solid tumors. - https://trisaluslifesci.com/trisalus-life-sciences-and-md-anderson-announce-strategic-research-collaboration-to-evaluate-treatment-of-solid-tumors/
• Philips and Ibex Medical Analytics team to accelerate adoption of AI-powered digital pathology. - https://ibex-ai.com/press/philips-and-ibex/
• Biognosys announces strategic agreement with Siemens Healthineers. - https://biognosys.com/news/biognosys-announces-strategic-agreement-with-siemens-healthineers/
• RubrYc Therapeutics announces a research collaboration and licensing option agreement with zai labs. - https://www.rubryc.com/news/rubryc-therapeutics-announces-research-collaboration-and-license-option-agreement-zai-labs
• TILT Biotherapeutics and MSD to collaborate on clinical trial of adenoviral cancer immunotherapeutic TILT-123 in combination with Keytruda® (pembrolizumab) for ovarian cancer. - https://tiltbio.com/news-events/
• Boehringer Ingelheim and MD Anderson expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer. - https://www.boehringer-ingelheim.com/press-release/expanded-collaboration-md-anderson
• ROSALIND, HELiXrUS and Geninus partner to bring powerful new single cell analysis services to cancer researchers. - https://www.businesswire.com/news/home/20210415005348/en
• Amgen and Neogenomics partner to expand biomarker testing access in NSCLC. - https://www.amgen.com/newsroom/press-releases/2021/04/amgen-launches-biomarker-assist-a-program-to-help-more-patients-with-nonsmall-cell-lung-cancer-gain-access-to-biomarker-testing
• Astrazeneca, Loxo Oncology at Lilly, and Invitae Corporation join the access to comprehensive genomic profiling coalition. - https://www.prnewswire.com/news-releases/astrazeneca-loxo-oncology-at-lilly-and-invitae-corporation-join-the-access-to-comprehensive-genomic-profiling-coalition-301270830.html?tc=eml_cleartime
• Northshore and Sema4 launch system-wide genomics program to improve primary and specialty care with data-driven insights. - https://sema4.com/news/northshore-and-sema4-partnership/
• Kaiku Health joins forces with Novartis for melanoma monitoring and support. - https://www.mobihealthnews.com/news/kaiku-health-joins-forces-novartis-melanoma-monitoring-and-support
• Illumina and Kartos Therapeutics announce new oncology partnership to develop an NGS-based TP53 companion diagnostic. - https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=12b6e4a6-3f52-407e-8200-8fa72712a980
• The Aptorum Group enters into a material transfer and exclusive option license rights agreement with Yale University for its novel immunomodulators with the potential to target autoimmune and oncological diseases. - https://ir.aptorumgroup.com/news-releases/news-release-details/aptorum-group-enters-material-transfer-and-exclusive-option
• Paige and Leica Biosystems partner to expand access to computational pathology products for pathology and oncology research. - https://www.paige.ai/resources/paige-and-leica-biosystems-partner-to-expand-access
• Pieris Pharmaceuticals and Boston Pharmaceuticals enter into an exclusive worldwide product license for PRS-342, a 4-1BB/GPC3 immuno-oncology bispecific. - https://www.pieris.com/news-and-events/press-releases/detail/658/pieris-pharmaceuticals-and-boston-pharmaceuticals-enter
• Guardant Health announces collaboration with Daiichi Sankyo to develop Guardant360® CDx as a companion diagnostic for Enhertu® in advanced metastatic non-small cell lung cancer. - https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Announces-Collaboration-With-Daiichi-Sankyo-to-Develop-Guardant360-CDx-as-a-Companion-Diagnostic-for-Enhertu-in-Advanced-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx
• Castle Biosciences signs definitive agreement to acquire Myriad myPath® Laboratory. - https://ir.castlebiosciences.com/news-releases/news-release-details/castle-biosciences-signs-definitive-agreement-acquire-myriad
• BostonGene and the Medical College of Wisconsin announce research collaboration. - https://bostongene.com/bostongene-and-the-medical-college-of-wisconsin-announce-research-collaboration/
• Mirum Pharmaceuticals and CANbridge pharmaceuticals enter into exclusive licensing agreement to develop and commercialize maralixibat in greater China for rare liver diseases. - https://ir.mirumpharma.com/news-releases/news-release-details/mirum-pharmaceuticals-and-canbridge-pharmaceuticals-enter

 Giovanni Dothel, PhD - gdothel@ipbadvisors.com - Inflection Point Biomedical Advisors

Jaume Calafell - jcalafell@ipbadvisors.com - Inflection Point Biomedical Advisors